ID SYI_BACCQ Reviewed; 921 AA. AC B9IVX2; DT 28-JUL-2009, integrated into UniProtKB/Swiss-Prot. DT 24-MAR-2009, sequence version 1. DT 27-MAR-2024, entry version 83. DE RecName: Full=Isoleucine--tRNA ligase {ECO:0000255|HAMAP-Rule:MF_02002}; DE EC=6.1.1.5 {ECO:0000255|HAMAP-Rule:MF_02002}; DE AltName: Full=Isoleucyl-tRNA synthetase {ECO:0000255|HAMAP-Rule:MF_02002}; DE Short=IleRS {ECO:0000255|HAMAP-Rule:MF_02002}; GN Name=ileS {ECO:0000255|HAMAP-Rule:MF_02002}; GN OrderedLocusNames=BCQ_3681; OS Bacillus cereus (strain Q1). OC Bacteria; Bacillota; Bacilli; Bacillales; Bacillaceae; Bacillus; OC Bacillus cereus group. OX NCBI_TaxID=361100; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RC STRAIN=Q1; RX PubMed=19060151; DOI=10.1128/jb.01629-08; RA Xiong Z., Jiang Y., Qi D., Lu H., Yang F., Yang J., Chen L., Sun L., Xu X., RA Xue Y., Zhu Y., Jin Q.; RT "Complete genome sequence of the extremophilic Bacillus cereus strain Q1 RT with industrial applications."; RL J. Bacteriol. 191:1120-1121(2009). CC -!- FUNCTION: Catalyzes the attachment of isoleucine to tRNA(Ile). As IleRS CC can inadvertently accommodate and process structurally similar amino CC acids such as valine, to avoid such errors it has two additional CC distinct tRNA(Ile)-dependent editing activities. One activity is CC designated as 'pretransfer' editing and involves the hydrolysis of CC activated Val-AMP. The other activity is designated 'posttransfer' CC editing and involves deacylation of mischarged Val-tRNA(Ile). CC {ECO:0000255|HAMAP-Rule:MF_02002}. CC -!- CATALYTIC ACTIVITY: CC Reaction=ATP + L-isoleucine + tRNA(Ile) = AMP + diphosphate + L- CC isoleucyl-tRNA(Ile); Xref=Rhea:RHEA:11060, Rhea:RHEA-COMP:9666, CC Rhea:RHEA-COMP:9695, ChEBI:CHEBI:30616, ChEBI:CHEBI:33019, CC ChEBI:CHEBI:58045, ChEBI:CHEBI:78442, ChEBI:CHEBI:78528, CC ChEBI:CHEBI:456215; EC=6.1.1.5; Evidence={ECO:0000255|HAMAP- CC Rule:MF_02002}; CC -!- COFACTOR: CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000255|HAMAP- CC Rule:MF_02002}; CC Note=Binds 1 zinc ion per subunit. {ECO:0000255|HAMAP-Rule:MF_02002}; CC -!- SUBUNIT: Monomer. {ECO:0000255|HAMAP-Rule:MF_02002}. CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000255|HAMAP-Rule:MF_02002}. CC -!- DOMAIN: IleRS has two distinct active sites: one for aminoacylation and CC one for editing. The misactivated valine is translocated from the CC active site to the editing site, which sterically excludes the CC correctly activated isoleucine. The single editing site contains two CC valyl binding pockets, one specific for each substrate (Val-AMP or Val- CC tRNA(Ile)). {ECO:0000255|HAMAP-Rule:MF_02002}. CC -!- SIMILARITY: Belongs to the class-I aminoacyl-tRNA synthetase family. CC IleS type 1 subfamily. {ECO:0000255|HAMAP-Rule:MF_02002}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; CP000227; ACM14109.1; -; Genomic_DNA. DR AlphaFoldDB; B9IVX2; -. DR SMR; B9IVX2; -. DR KEGG; bcq:BCQ_3681; -. DR HOGENOM; CLU_001493_7_2_9; -. DR Proteomes; UP000000441; Chromosome. DR GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell. DR GO; GO:0002161; F:aminoacyl-tRNA editing activity; IEA:InterPro. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-UniRule. DR GO; GO:0004822; F:isoleucine-tRNA ligase activity; IEA:UniProtKB-UniRule. DR GO; GO:0000049; F:tRNA binding; IEA:InterPro. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-UniRule. DR GO; GO:0006428; P:isoleucyl-tRNA aminoacylation; IEA:UniProtKB-UniRule. DR CDD; cd07960; Anticodon_Ia_Ile_BEm; 1. DR CDD; cd00818; IleRS_core; 1. DR Gene3D; 1.10.730.20; -; 1. DR Gene3D; 3.40.50.620; HUPs; 2. DR Gene3D; 1.10.10.830; Ile-tRNA synthetase CP2 domain-like; 1. DR Gene3D; 3.90.740.10; Valyl/Leucyl/Isoleucyl-tRNA synthetase, editing domain; 1. DR HAMAP; MF_02002; Ile_tRNA_synth_type1; 1. DR InterPro; IPR001412; aa-tRNA-synth_I_CS. DR InterPro; IPR002300; aa-tRNA-synth_Ia. DR InterPro; IPR033708; Anticodon_Ile_BEm. DR InterPro; IPR002301; Ile-tRNA-ligase. DR InterPro; IPR023585; Ile-tRNA-ligase_type1. DR InterPro; IPR013155; M/V/L/I-tRNA-synth_anticd-bd. DR InterPro; IPR014729; Rossmann-like_a/b/a_fold. DR InterPro; IPR009080; tRNAsynth_Ia_anticodon-bd. DR InterPro; IPR009008; Val/Leu/Ile-tRNA-synth_edit. DR InterPro; IPR010663; Znf_FPG/IleRS. DR NCBIfam; TIGR00392; ileS; 1. DR PANTHER; PTHR42765:SF1; ISOLEUCINE--TRNA LIGASE, MITOCHONDRIAL; 1. DR PANTHER; PTHR42765; SOLEUCYL-TRNA SYNTHETASE; 1. DR Pfam; PF08264; Anticodon_1; 1. DR Pfam; PF00133; tRNA-synt_1; 1. DR Pfam; PF06827; zf-FPG_IleRS; 1. DR PRINTS; PR00984; TRNASYNTHILE. DR SUPFAM; SSF47323; Anticodon-binding domain of a subclass of class I aminoacyl-tRNA synthetases; 1. DR SUPFAM; SSF52374; Nucleotidylyl transferase; 1. DR SUPFAM; SSF50677; ValRS/IleRS/LeuRS editing domain; 1. DR PROSITE; PS00178; AA_TRNA_LIGASE_I; 1. PE 3: Inferred from homology; KW Aminoacyl-tRNA synthetase; ATP-binding; Cytoplasm; Ligase; Metal-binding; KW Nucleotide-binding; Protein biosynthesis; Zinc. FT CHAIN 1..921 FT /note="Isoleucine--tRNA ligase" FT /id="PRO_1000189128" FT MOTIF 57..67 FT /note="'HIGH' region" FT MOTIF 593..597 FT /note="'KMSKS' region" FT BINDING 552 FT /ligand="L-isoleucyl-5'-AMP" FT /ligand_id="ChEBI:CHEBI:178002" FT /evidence="ECO:0000255|HAMAP-Rule:MF_02002" FT BINDING 596 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|HAMAP-Rule:MF_02002" FT BINDING 888 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000255|HAMAP-Rule:MF_02002" FT BINDING 891 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000255|HAMAP-Rule:MF_02002" FT BINDING 908 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000255|HAMAP-Rule:MF_02002" FT BINDING 911 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000255|HAMAP-Rule:MF_02002" SQ SEQUENCE 921 AA; 104550 MW; 715ABAF58FED9C2E CRC64; MEYKNTLLMP KTEFPMRGNL PKREPAMQEK WAEMNIYEKV QEHTKGRPLF VLHDGPPYAN GDIHMGHALN KVLKDFIVRY KSMTGFCAPY VPGWDTHGLP IEQALTNKGV KRKEMTVAEF RKLCAEYAYE QVERQREQFK RLGVRADWDN PYITLEPAYE AQQIKVFGDM AKKGYIYKGQ KPVYWSPTSE SALAEAEIEY QDKKSASIYV AFPVKDGKNV LEGDEKYIIW TTTPWTLPAN LGISVHPELE YAIVKVNGEK YIIASELFET VAKTLEWENA EVVKTVKGSE LEYTVAKHPF YDRDSLVMLG DHVTTDAGTG CVHTAPGHGE DDFIVGKKYG LEVLCPVDDK GVLTEEAPGF EGLFYDKANK PITEKLEEVG ALLKLTFITH SYPHDWRTKK PIIFRATAQW FASIEAFRKE LLEAVAETKW VPAWGETRLH NMVRDRGDWC ISRQRAWGVP IPVFYAENGD PIITDETINH VADLFREHGS NVWFEREAKD LLPEGFTHSG SPNGEFRKET DIMDVWFDSG SSHQAVLEER DDLQRPADLY LEGSDQYRGW FNSSLSTAVA VTGKAPYKGV LSHGFVLDGE GRKMSKSIGN IVVPKKIMDQ LGGDILRLWV SSVDYQSDVR ISDDILKQVA EVYRKIRNTF RFLLGNLDDF KPSENTVAVA ELREVDRYML VKLNDLITKV KEAYETYDFA AVYHAIHNFC TIDLSSFYLD FAKDILYIEG ANHEDRRAIQ TVLYDVLVAL TKLVTPILPH TADEVWPYIP GVTEESVQLT DMPEAVQLDG AEALKTKWDA FMTLRDDVLK ALEVARNEKV IGKSLNASIT LYPTAEMKAM LESINEDLKQ LFIVSEYKLG GMMEEAPADA PKYEHTAVVV VQATGETCER CWVVSETIGK DAEHETLCER CATVVKENYV K //